Get 20% Off Market Intelligence Reports With Code ONLINE20 – Track Global Tariffs, Economic Shifts, and Sector Transformations
What Is the Current Market Size and Growth Rate of the Oncology Adjuvants Market?
The oncology adjuvants market size has grown strongly in recent years. It will grow from $1.59 billion in 2024 to $1.73 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increasing cancer incidence worldwide, growing need for better preclinical predictability, increasing utilization of patient-derived xenograft (PDX) models, expanding reliance on in vivo efficacy data, and growing focus on early-stage immuno-oncology.
The oncology adjuvants market size is expected to see strong growth in the next few years. It will grow to $2.35 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to growing focus on human-relevant models, increasing demand for precision oncology, the rise in immuno-oncology treatment, growing demand for high-throughput screening models, and expanding interest in rare cancer models. Major trends in the forecast period include integration of nanotechnology, adjuvants enhancing CAR-T cell therapies, advancement in immuno-oncology adjuvants, adjuvants enhancing CAR-T cell therapies, and artificial intelligence and machine learning.
Claim your free report sample now:
What Are the Key Drivers of the Oncology Adjuvants Market?
The increasing demand for personalized medicine is expected to propel the growth of the oncology adjuvants market going forward. Personalized medicine refers to a medical model that uses information about a person’s genes and lifestyle environment to tailor treatments and healthcare to their specific needs. Personalized medicine is rising due to advancements in genetic and molecular profiling, which enable treatments tailored to an individual’s unique biological makeup, improving effectiveness and reducing adverse effects. Oncology adjuvants help personalized medicine by allowing the customization of additional cancer treatments based on a patient’s unique genetic makeup and tumor characteristics, ensuring that therapies target residual cancer cells effectively while minimizing unnecessary side effects. For instance, in February 2023, according to the Personalized Medicine Coalition, a US-based professional membership organization, in 2022, the approval of 12 new personalized medicines represented approximately 34% of all newly approved therapies, indicating a substantial increase from previous years. Therefore, the increasing demand for personalized medicine is driving the growth of the oncology adjuvants market.
How Is the Oncology Adjuvants Market Segmented?
The oncology adjuvants market covered in this report is segmented
1) By Type Of Adjuvant: Chemotherapy Adjuvants, Radiation Adjuvants, Immunotherapy Adjuvants, Hormonal Adjuvants, Targeted Therapy Adjuvants
2) By Administration Route: Oral, Intravenous, Subcutaneous, Topical, Intramuscular
3) By Indication: Breast Cancer, Glioblastoma, Lung Cancer, Colorectal Cancer, Ovarian Cancer, Sarcoma, Prostate Cancer, Other Indications
4) By End User: Cancer Research Institute, Cancer Hospitals
Subsegments:
1) By Chemotherapy Adjuvants: Alkylating Agents, Antimetabolites, Anthracyclines, Plant Alkaloids, Topoisomerase Inhibitors, Platinum-Based Compounds, Others
2) By Radiation Adjuvants: Radiosensitizers, Radioprotectors, Hypoxic Cell Sensitizers, Deoxyribonucleic Acid (DNA) Repair Inhibitors, Immune Modulating Agents Combined With Radiation
3) By Immunotherapy Adjuvants: Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Adoptive Cell Transfer, Immune Modulating Agents
4) By Hormonal Adjuvants: Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Gonadotropin-Releasing Hormone Agonists Or Antagonists, Androgen Receptor Inhibitors, Estrogen Receptor Downregulators
5) By Targeted Therapy Adjuvants: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, mTOR Inhibitors, v-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) Or Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors, Vascular Endothelial Growth Factor (VEGF) Inhibitors
Which Trends Are Expected to Redefine the Oncology Adjuvants Market Landscape?
Major companies operating in the oncology adjuvants market are focusing on developing advanced solutions, such as immune checkpoint inhibitor adjuvant therapy to enhance post-surgical treatment efficacy, and improve overall patient survival by harnessing the body’s immune system to target residual tumor cells. Immune checkpoint inhibitor adjuvant therapy refers to the use of drugs that block immune checkpoint proteins such as PD-1, PD-L1, or CTLA-4 that normally act as brakes on the immune system. For instance, in January 2023, Merck & Co., Inc., a US-based pharmaceutical company, launched KEYTRUDA (pembrolizumab) as an adjuvant treatment, which received approval from the Food and Drug Administration (FDA). It follows surgical resection and platinum-based chemotherapy for patients with Stage IB (T2a =4 centimeters), II, or IIIA non-small cell lung cancer (NSCLC). KEYTRUDA (pembrolizumab) offers targeted immune checkpoint inhibition by blocking the PD-1 receptor, thereby restoring the immune system’s ability to detect and attack cancer cells. It provides an effective adjuvant treatment option for patients with non-small cell lung cancer (NSCLC) following surgery and chemotherapy, helping to reduce the risk of cancer recurrence and improve overall survival. Additionally, KEYTRUDA supports personalized cancer therapy by leveraging the patient’s immune response, making it a vital tool in modern immuno-oncology.
Which Are the Top Companies in the Oncology Adjuvants Market?
Major companies operating in the oncology adjuvants market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, SEPPIC, Ipsen S.A., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Croda International Plc, Dynavax Technologies Corporation, Agenus Inc., Aurorium, Elicio Therapeutics Inc.
Get the full oncology adjuvants market report here:
Which Region Is Projected to Account for the Largest Share of the Oncology Adjuvants Market?
North America was the largest region in the oncology adjuvants market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology adjuvants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
Comments
Post a Comment